Clene Inc. (CLNN) · Nov 4, 2026 · Earnings
Beat — Diluted EPS $0.05 vs ~$0.46 loss consensus
Clene earnings beat estimates, while the ALS NDA and financing milestones were largely already known. The real update is runway into early 2027.
Clene is a late-stage biotech trying to move CNM-Au8 for ALS from Phase 2 evidence into an accelerated-approval review, with a confirmatory Phase 3 trial planned afterward. The core milestones—the NDA submission and $4 million financing—were already announced in October and September, while the prior quarter had already targeted an early-fourth-quarter NDA and warned that cash only reached late fourth quarter.
The headline earnings beat is real but low quality. Clene reported diluted EPS of $0.05 versus a published consensus loss of roughly $0.46, but the swing was driven mainly by a $10.3 million gain from changes in the fair value of warrant and derivative liabilities—not by revenue or improving drug economics. The company reported net income of $3.9 million versus an $8.8 million loss a year earlier.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior |
|---|---|---|---|
| Diluted EPS (Financial Results) | $0.05 | $(0.85) | $(0.46) consensus |
| R&D expense (Financial Results) | $4.4M (+27%) | $3.5M | |
| G&A expense (Financial Results) | $1.9M (-10%) | $2.2M | |
| Cash (Balance Sheet) | $9.9M | $5.2M at Dec. 31, 2025 | |
| Operating cash used, nine months (Cash Flow) | $11.7M | $13.7M |
The business remains on the regulatory path, but this filing does not materially improve the approval odds. The company confirms that it submitted the NDA in October and plans to start RESTORE-ALS in the second quarter of 2027; those are meaningful execution steps, but the submission itself was already public, and the filing provides no new clinical efficacy result or FDA acceptance. 〔0〕 〔1〕
Financing buys time, not self-sufficiency. The September offering lifted cash to $9.9 million and extends the stated operating runway from the prior late-fourth-quarter target into mid-first quarter 2027, but Clene is still loss-making on an operating basis and may need the $6.7 million to $7.8 million of warrant proceeds or additional capital. 〔2〕
Bottom line: This is a narrow earnings beat and a confirmation that Clene is progressing through the ALS regulatory process, but the important milestones were already known and the profit was mostly accounting-driven. The filing modestly strengthens near-term execution visibility without changing the underlying clinical or funding risk story.
FDA acceptance decision on the CNM-Au8 NDA
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!